other material
confidence high
sentiment positive
materiality 0.50
bioAffinity Technologies wins Hong Kong patent for CyPath Lung lung cancer diagnostic
bioAffinity Technologies, Inc.
- Hong Kong IP Department granted Patent No. HK40048460 covering flow cytometry and fluorescent markers in sputum for lung cancer prediction.
- Patent complements 2025 China patent; strengthens IP in Asia, which accounts for ~1.6M new lung cancer cases annually.
- CyPath Lung clinical trial data: 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV in high-risk patients with nodules <20mm.
- Company holds patents/pending in US, Australia, Canada, China, EU, Japan, Mexico, Singapore.